Protagonist Therapeutics Inc (PTGX)
30.74
-1.20
(-3.76%)
USD |
NASDAQ |
May 17, 16:00
30.74
0.00 (0.00%)
After-Hours: 20:00
Protagonist Therapeutics SG&A Expense (Quarterly): 14.91M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 14.91M |
| December 31, 2023 | 8.052M |
| September 30, 2023 | 7.662M |
| June 30, 2023 | 9.172M |
| March 31, 2023 | 8.605M |
| December 31, 2022 | 6.632M |
| September 30, 2022 | 6.901M |
| June 30, 2022 | 7.691M |
| March 31, 2022 | 10.52M |
| December 31, 2021 | 7.26M |
| September 30, 2021 | 7.256M |
| June 30, 2021 | 6.715M |
| March 31, 2021 | 5.965M |
| December 31, 2020 | 4.994M |
| September 30, 2020 | 4.891M |
| June 30, 2020 | 4.177M |
| March 31, 2020 | 4.576M |
| December 31, 2019 | 4.107M |
| September 30, 2019 | 4.015M |
| Date | Value |
|---|---|
| June 30, 2019 | 3.863M |
| March 31, 2019 | 3.764M |
| December 31, 2018 | 3.517M |
| September 30, 2018 | 3.361M |
| June 30, 2018 | 3.178M |
| March 31, 2018 | 3.642M |
| December 31, 2017 | 3.071M |
| September 30, 2017 | 2.593M |
| June 30, 2017 | 3.124M |
| March 31, 2017 | 2.991M |
| December 31, 2016 | 2.574M |
| September 30, 2016 | 1.577M |
| June 30, 2016 | 1.395M |
| March 31, 2016 | 1.415M |
| December 31, 2015 | 0.808M |
| September 30, 2015 | 0.863M |
| June 30, 2015 | 0.786M |
| March 31, 2015 | 0.506M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
3.863M
Minimum
Jun 2019
14.91M
Maximum
Mar 2024
6.898M
Average
6.808M
Median
SG&A Expense (Quarterly) Benchmarks
| Lifecore Biomedical Inc | 11.69M |
| SELLAS Life Sciences Group Inc | 4.534M |
| Akebia Therapeutics Inc | 25.44M |
| Immuneering Corp | 4.116M |
| Moderna Inc | 274.00M |